| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endovascular Procedures | 41 | 2025 | 655 | 7.260 |
Why?
|
| Blood Vessel Prosthesis Implantation | 28 | 2024 | 318 | 5.990 |
Why?
|
| Peripheral Arterial Disease | 20 | 2025 | 173 | 5.860 |
Why?
|
| Aortic Aneurysm, Abdominal | 24 | 2025 | 255 | 5.490 |
Why?
|
| Vascular Surgical Procedures | 27 | 2025 | 263 | 5.170 |
Why?
|
| Intermittent Claudication | 11 | 2025 | 56 | 4.140 |
Why?
|
| Blood Vessel Prosthesis | 18 | 2024 | 225 | 2.920 |
Why?
|
| Lower Extremity | 11 | 2024 | 166 | 2.810 |
Why?
|
| Treatment Outcome | 63 | 2025 | 5686 | 2.070 |
Why?
|
| Ischemia | 9 | 2022 | 205 | 2.060 |
Why?
|
| Risk Factors | 51 | 2025 | 5356 | 1.950 |
Why?
|
| Retrospective Studies | 60 | 2025 | 6660 | 1.790 |
Why?
|
| Time Factors | 47 | 2025 | 3771 | 1.720 |
Why?
|
| Postoperative Complications | 20 | 2024 | 1309 | 1.600 |
Why?
|
| Aortic Aneurysm | 4 | 2021 | 87 | 1.520 |
Why?
|
| Risk Assessment | 31 | 2025 | 2081 | 1.510 |
Why?
|
| Endoleak | 5 | 2024 | 42 | 1.440 |
Why?
|
| Quality Indicators, Health Care | 9 | 2025 | 338 | 1.400 |
Why?
|
| General Surgery | 3 | 2025 | 211 | 1.390 |
Why?
|
| Exercise Therapy | 4 | 2025 | 104 | 1.300 |
Why?
|
| Stents | 10 | 2024 | 503 | 1.290 |
Why?
|
| Hospital Mortality | 17 | 2025 | 876 | 1.270 |
Why?
|
| Aortic Aneurysm, Thoracic | 5 | 2022 | 116 | 1.240 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2025 | 712 | 1.200 |
Why?
|
| Aged | 62 | 2025 | 14443 | 1.180 |
Why?
|
| Humans | 110 | 2025 | 63465 | 1.150 |
Why?
|
| Aged, 80 and over | 35 | 2025 | 5462 | 1.150 |
Why?
|
| Limb Salvage | 6 | 2022 | 70 | 1.080 |
Why?
|
| Male | 73 | 2025 | 29907 | 1.080 |
Why?
|
| Quality Improvement | 6 | 2025 | 443 | 1.040 |
Why?
|
| Female | 74 | 2025 | 32890 | 1.020 |
Why?
|
| Endarterectomy, Carotid | 7 | 2024 | 91 | 1.020 |
Why?
|
| Databases, Factual | 20 | 2025 | 873 | 1.010 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2021 | 49 | 1.010 |
Why?
|
| Vascular Patency | 9 | 2024 | 139 | 0.980 |
Why?
|
| Consensus | 2 | 2025 | 208 | 0.970 |
Why?
|
| Clinical Decision-Making | 3 | 2023 | 165 | 0.940 |
Why?
|
| Pancreatic Neoplasms | 8 | 2010 | 341 | 0.890 |
Why?
|
| Cultural Diversity | 1 | 2025 | 53 | 0.860 |
Why?
|
| Middle Aged | 47 | 2025 | 17609 | 0.850 |
Why?
|
| Fibrinolytic Agents | 1 | 2025 | 169 | 0.850 |
Why?
|
| Registries | 17 | 2025 | 888 | 0.820 |
Why?
|
| Career Choice | 1 | 2025 | 131 | 0.820 |
Why?
|
| Minority Groups | 1 | 2025 | 139 | 0.820 |
Why?
|
| Benchmarking | 5 | 2025 | 136 | 0.810 |
Why?
|
| Practice Guidelines as Topic | 6 | 2025 | 724 | 0.810 |
Why?
|
| Iliac Aneurysm | 1 | 2023 | 11 | 0.800 |
Why?
|
| Myocardial Ischemia | 2 | 2014 | 119 | 0.800 |
Why?
|
| Vascular Grafting | 4 | 2018 | 39 | 0.790 |
Why?
|
| Patient Readmission | 3 | 2024 | 430 | 0.780 |
Why?
|
| Liver Neoplasms | 3 | 2010 | 297 | 0.780 |
Why?
|
| Carotid Stenosis | 4 | 2021 | 105 | 0.770 |
Why?
|
| Surgeons | 7 | 2021 | 183 | 0.770 |
Why?
|
| United States | 37 | 2025 | 7842 | 0.770 |
Why?
|
| Decision Support Techniques | 3 | 2025 | 196 | 0.750 |
Why?
|
| Walking | 2 | 2023 | 238 | 0.740 |
Why?
|
| Aorta, Abdominal | 2 | 2022 | 61 | 0.740 |
Why?
|
| Prosthesis Design | 12 | 2022 | 229 | 0.730 |
Why?
|
| Patient Discharge | 3 | 2024 | 512 | 0.720 |
Why?
|
| Hepatectomy | 4 | 2010 | 63 | 0.720 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2021 | 422 | 0.710 |
Why?
|
| Reimbursement, Incentive | 2 | 2019 | 29 | 0.710 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 89 | 0.670 |
Why?
|
| Spinal Cord Ischemia | 1 | 2020 | 16 | 0.660 |
Why?
|
| Celiac Artery | 1 | 2019 | 14 | 0.630 |
Why?
|
| Pancreatectomy | 6 | 2010 | 101 | 0.630 |
Why?
|
| Drainage | 1 | 2020 | 154 | 0.610 |
Why?
|
| Baths | 1 | 2019 | 7 | 0.610 |
Why?
|
| Hygiene | 1 | 2019 | 13 | 0.610 |
Why?
|
| Patient Care Bundles | 1 | 2019 | 12 | 0.610 |
Why?
|
| Chlorhexidine | 1 | 2019 | 19 | 0.600 |
Why?
|
| Intraoperative Care | 1 | 2019 | 38 | 0.600 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2019 | 30 | 0.600 |
Why?
|
| Physician Incentive Plans | 1 | 2018 | 9 | 0.590 |
Why?
|
| Internship and Residency | 3 | 2021 | 805 | 0.570 |
Why?
|
| Economics, Hospital | 1 | 2017 | 15 | 0.560 |
Why?
|
| Guideline Adherence | 3 | 2025 | 305 | 0.560 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 115 | 0.560 |
Why?
|
| Health Expenditures | 2 | 2017 | 122 | 0.540 |
Why?
|
| Patient Selection | 6 | 2023 | 490 | 0.530 |
Why?
|
| Device Approval | 1 | 2017 | 13 | 0.530 |
Why?
|
| Survival Rate | 10 | 2021 | 852 | 0.520 |
Why?
|
| Computed Tomography Angiography | 5 | 2021 | 126 | 0.510 |
Why?
|
| Inpatients | 2 | 2019 | 304 | 0.510 |
Why?
|
| Comorbidity | 14 | 2024 | 1124 | 0.490 |
Why?
|
| Reoperation | 6 | 2019 | 293 | 0.470 |
Why?
|
| Medicare | 6 | 2022 | 612 | 0.470 |
Why?
|
| Quality of Health Care | 1 | 2018 | 519 | 0.440 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2020 | 44 | 0.430 |
Why?
|
| Aortic Diseases | 3 | 2023 | 74 | 0.430 |
Why?
|
| Models, Biological | 1 | 2019 | 1178 | 0.430 |
Why?
|
| Fee-for-Service Plans | 3 | 2020 | 69 | 0.420 |
Why?
|
| Hospitals, High-Volume | 3 | 2025 | 35 | 0.410 |
Why?
|
| Education, Medical, Graduate | 4 | 2021 | 351 | 0.390 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 916 | 0.370 |
Why?
|
| Hospitals, Low-Volume | 2 | 2025 | 21 | 0.370 |
Why?
|
| Chi-Square Distribution | 10 | 2016 | 418 | 0.360 |
Why?
|
| Ultrasonography, Doppler, Duplex | 3 | 2021 | 50 | 0.350 |
Why?
|
| Aortic Rupture | 3 | 2016 | 55 | 0.340 |
Why?
|
| Needs Assessment | 2 | 2025 | 198 | 0.340 |
Why?
|
| Prospective Studies | 8 | 2023 | 3294 | 0.340 |
Why?
|
| Aortography | 6 | 2022 | 62 | 0.330 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 146 | 0.310 |
Why?
|
| Digestive System Diseases | 1 | 2009 | 14 | 0.310 |
Why?
|
| Elective Surgical Procedures | 4 | 2025 | 123 | 0.310 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 36 | 0.310 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 31 | 0.310 |
Why?
|
| Medicare Access and CHIP Reauthorization Act of 2015 | 2 | 2019 | 2 | 0.310 |
Why?
|
| New England | 4 | 2016 | 274 | 0.300 |
Why?
|
| Predictive Value of Tests | 7 | 2025 | 1094 | 0.300 |
Why?
|
| Relative Value Scales | 2 | 2020 | 15 | 0.300 |
Why?
|
| Clinical Coding | 3 | 2018 | 44 | 0.290 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 178 | 0.280 |
Why?
|
| Chronic Disease | 3 | 2020 | 753 | 0.270 |
Why?
|
| Quality of Life | 3 | 2023 | 1228 | 0.260 |
Why?
|
| Amyloid | 2 | 2025 | 70 | 0.260 |
Why?
|
| Physician's Role | 2 | 2018 | 124 | 0.250 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2462 | 0.250 |
Why?
|
| Societies, Medical | 3 | 2025 | 379 | 0.240 |
Why?
|
| Renal Dialysis | 2 | 2018 | 198 | 0.240 |
Why?
|
| Massachusetts | 7 | 2020 | 2075 | 0.240 |
Why?
|
| Stroke | 3 | 2021 | 1196 | 0.240 |
Why?
|
| Computer Simulation | 2 | 2019 | 477 | 0.240 |
Why?
|
| SEER Program | 6 | 2010 | 74 | 0.240 |
Why?
|
| Clinical Competence | 3 | 2021 | 727 | 0.240 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 1653 | 0.240 |
Why?
|
| Logistic Models | 11 | 2016 | 1277 | 0.230 |
Why?
|
| Pneumococcal Infections | 1 | 2025 | 38 | 0.230 |
Why?
|
| Streptococcus pneumoniae | 1 | 2025 | 66 | 0.230 |
Why?
|
| Evidence-Based Medicine | 2 | 2025 | 462 | 0.230 |
Why?
|
| Phosphorylcholine | 1 | 2025 | 44 | 0.230 |
Why?
|
| Mobility Limitation | 1 | 2025 | 49 | 0.230 |
Why?
|
| Patient Compliance | 2 | 2019 | 360 | 0.220 |
Why?
|
| C-Reactive Protein | 1 | 2025 | 166 | 0.220 |
Why?
|
| Aneurysm, Infected | 2 | 2015 | 13 | 0.220 |
Why?
|
| Hospitals | 5 | 2010 | 393 | 0.220 |
Why?
|
| Patient Preference | 1 | 2024 | 84 | 0.210 |
Why?
|
| Pilot Projects | 2 | 2025 | 1008 | 0.210 |
Why?
|
| Health Services Misuse | 1 | 2023 | 18 | 0.210 |
Why?
|
| Workload | 2 | 2021 | 126 | 0.210 |
Why?
|
| Unnecessary Procedures | 1 | 2023 | 49 | 0.200 |
Why?
|
| Hospital Costs | 4 | 2020 | 126 | 0.200 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2021 | 62 | 0.200 |
Why?
|
| Aneurysm, False | 1 | 2023 | 52 | 0.190 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 348 | 0.190 |
Why?
|
| Odds Ratio | 7 | 2016 | 768 | 0.190 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 226 | 0.190 |
Why?
|
| Natural Language Processing | 1 | 2022 | 48 | 0.190 |
Why?
|
| Length of Stay | 7 | 2020 | 813 | 0.190 |
Why?
|
| Retreatment | 2 | 2019 | 47 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 59 | 0.190 |
Why?
|
| Insulins | 1 | 2022 | 15 | 0.190 |
Why?
|
| Mutation, Missense | 2 | 2020 | 186 | 0.180 |
Why?
|
| Sex Characteristics | 1 | 2023 | 203 | 0.180 |
Why?
|
| Leadership | 3 | 2021 | 206 | 0.180 |
Why?
|
| Fiber Optic Technology | 1 | 2021 | 24 | 0.180 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 242 | 0.180 |
Why?
|
| Aorta | 2 | 2023 | 114 | 0.180 |
Why?
|
| Physicians | 2 | 2022 | 470 | 0.180 |
Why?
|
| Prognosis | 4 | 2021 | 1748 | 0.180 |
Why?
|
| Sexism | 1 | 2021 | 31 | 0.180 |
Why?
|
| Physicians, Women | 1 | 2021 | 41 | 0.180 |
Why?
|
| Renal Artery | 1 | 2021 | 37 | 0.170 |
Why?
|
| Iliac Artery | 1 | 2021 | 49 | 0.170 |
Why?
|
| Reimbursement Mechanisms | 2 | 2018 | 40 | 0.170 |
Why?
|
| Health Facilities | 1 | 2020 | 43 | 0.170 |
Why?
|
| Angioplasty, Balloon | 1 | 2020 | 58 | 0.170 |
Why?
|
| Cutis Laxa | 1 | 2020 | 7 | 0.170 |
Why?
|
| Current Procedural Terminology | 2 | 2020 | 16 | 0.170 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 49 | 0.170 |
Why?
|
| Intraoperative Complications | 1 | 2021 | 91 | 0.170 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 107 | 0.170 |
Why?
|
| Post-Dural Puncture Headache | 1 | 2020 | 5 | 0.170 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 21 | 0.170 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2020 | 35 | 0.170 |
Why?
|
| Equipment and Supplies | 1 | 2020 | 19 | 0.170 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2020 | 9 | 0.170 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2020 | 11 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 456 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 46 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 153 | 0.160 |
Why?
|
| Incidence | 3 | 2018 | 1377 | 0.160 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2020 | 15 | 0.160 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 1553 | 0.160 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 730 | 0.160 |
Why?
|
| Documentation | 2 | 2018 | 128 | 0.160 |
Why?
|
| Anticoagulants | 1 | 2024 | 495 | 0.160 |
Why?
|
| Data Accuracy | 2 | 2018 | 32 | 0.160 |
Why?
|
| Patient Care Team | 3 | 2020 | 337 | 0.160 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2010 | 51 | 0.160 |
Why?
|
| Saphenous Vein | 1 | 2019 | 52 | 0.150 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2020 | 108 | 0.150 |
Why?
|
| Atherectomy | 1 | 2018 | 12 | 0.150 |
Why?
|
| Upper Extremity | 1 | 2018 | 54 | 0.150 |
Why?
|
| Forms and Records Control | 1 | 2018 | 15 | 0.140 |
Why?
|
| Healthcare Disparities | 3 | 2018 | 359 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Diagnosis-Related Groups | 1 | 2018 | 87 | 0.140 |
Why?
|
| Coronary Vasospasm | 1 | 2017 | 11 | 0.140 |
Why?
|
| Medical Records | 1 | 2018 | 137 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2012 | 275 | 0.140 |
Why?
|
| Young Adult | 3 | 2025 | 4695 | 0.140 |
Why?
|
| Rare Diseases | 1 | 2017 | 42 | 0.140 |
Why?
|
| International Classification of Diseases | 1 | 2018 | 136 | 0.130 |
Why?
|
| Contracts | 1 | 2017 | 6 | 0.130 |
Why?
|
| Centralized Hospital Services | 1 | 2017 | 6 | 0.130 |
Why?
|
| Regional Health Planning | 1 | 2017 | 10 | 0.130 |
Why?
|
| Skin | 1 | 2020 | 374 | 0.130 |
Why?
|
| beta 2-Microglobulin | 1 | 2017 | 49 | 0.130 |
Why?
|
| Negotiating | 1 | 2017 | 15 | 0.130 |
Why?
|
| Single-Domain Antibodies | 1 | 2017 | 18 | 0.130 |
Why?
|
| Angioplasty | 2 | 2022 | 55 | 0.130 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 5 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2019 | 569 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.130 |
Why?
|
| Self-Assessment | 1 | 2017 | 60 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 539 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Hospitals, Teaching | 1 | 2017 | 106 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 209 | 0.130 |
Why?
|
| Inservice Training | 1 | 2017 | 86 | 0.130 |
Why?
|
| Amyloidosis | 1 | 2017 | 66 | 0.130 |
Why?
|
| Critical Care | 1 | 2020 | 397 | 0.130 |
Why?
|
| Education, Medical, Continuing | 1 | 2017 | 96 | 0.130 |
Why?
|
| Computer-Assisted Instruction | 1 | 2017 | 80 | 0.130 |
Why?
|
| Models, Cardiovascular | 1 | 2017 | 79 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2016 | 123 | 0.130 |
Why?
|
| Recovery of Function | 2 | 2025 | 288 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 937 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2016 | 141 | 0.120 |
Why?
|
| Practice Management, Medical | 1 | 2015 | 21 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2020 | 206 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 761 | 0.110 |
Why?
|
| Treatment Failure | 2 | 2015 | 201 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2010 | 509 | 0.110 |
Why?
|
| Medicaid | 1 | 2017 | 362 | 0.100 |
Why?
|
| Turner Syndrome | 1 | 2013 | 9 | 0.100 |
Why?
|
| Troponin | 1 | 2013 | 38 | 0.100 |
Why?
|
| Subclavian Artery | 1 | 2013 | 26 | 0.100 |
Why?
|
| Patient Admission | 2 | 2018 | 198 | 0.100 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2010 | 12 | 0.100 |
Why?
|
| Tuberculosis, Cardiovascular | 1 | 2012 | 2 | 0.100 |
Why?
|
| Aneurysm | 1 | 2013 | 60 | 0.100 |
Why?
|
| BCG Vaccine | 1 | 2012 | 51 | 0.100 |
Why?
|
| Mycobacterium bovis | 1 | 2012 | 28 | 0.100 |
Why?
|
| Cryopreservation | 1 | 2012 | 30 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 373 | 0.100 |
Why?
|
| Hypertension | 1 | 2017 | 585 | 0.100 |
Why?
|
| Critical Illness | 2 | 2018 | 322 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2025 | 2109 | 0.090 |
Why?
|
| Adult | 5 | 2025 | 16829 | 0.090 |
Why?
|
| Bioprosthesis | 1 | 2012 | 42 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 264 | 0.090 |
Why?
|
| Colectomy | 2 | 2009 | 108 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 105 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 410 | 0.090 |
Why?
|
| Neuroectodermal Tumors | 1 | 2010 | 2 | 0.080 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2010 | 16 | 0.080 |
Why?
|
| Carotid Artery Diseases | 1 | 2010 | 66 | 0.080 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2010 | 9 | 0.080 |
Why?
|
| Program Evaluation | 3 | 2018 | 487 | 0.080 |
Why?
|
| Sarcoma | 1 | 2010 | 36 | 0.080 |
Why?
|
| Health Resources | 1 | 2010 | 95 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 89 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2009 | 138 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 87 | 0.080 |
Why?
|
| Diverticulitis | 1 | 2009 | 31 | 0.080 |
Why?
|
| Social Class | 1 | 2009 | 133 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2009 | 97 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 345 | 0.070 |
Why?
|
| Specialties, Surgical | 1 | 2008 | 48 | 0.070 |
Why?
|
| Organ Transplantation | 1 | 2008 | 54 | 0.070 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2008 | 90 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 311 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 663 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2008 | 156 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2009 | 422 | 0.060 |
Why?
|
| Age Factors | 4 | 2010 | 1559 | 0.060 |
Why?
|
| Amputees | 1 | 2025 | 3 | 0.060 |
Why?
|
| Artificial Limbs | 1 | 2025 | 5 | 0.060 |
Why?
|
| ROC Curve | 2 | 2020 | 282 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2009 | 492 | 0.060 |
Why?
|
| Paclitaxel | 1 | 2024 | 99 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2024 | 83 | 0.050 |
Why?
|
| Sex Factors | 2 | 2021 | 980 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2025 | 217 | 0.050 |
Why?
|
| Cardiovascular Agents | 1 | 2024 | 104 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2018 | 287 | 0.050 |
Why?
|
| Aspirin | 1 | 2024 | 171 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 464 | 0.050 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2022 | 42 | 0.050 |
Why?
|
| Child | 2 | 2023 | 4536 | 0.050 |
Why?
|
| Optical Fibers | 1 | 2021 | 10 | 0.050 |
Why?
|
| Committee Membership | 1 | 2021 | 8 | 0.050 |
Why?
|
| Technology | 1 | 2021 | 53 | 0.040 |
Why?
|
| Catheters | 1 | 2021 | 75 | 0.040 |
Why?
|
| Paraparesis | 1 | 2021 | 9 | 0.040 |
Why?
|
| Femoral Artery | 1 | 2022 | 110 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2021 | 78 | 0.040 |
Why?
|
| Protein Binding | 1 | 2025 | 1603 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2021 | 112 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 71 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 119 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 17 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 254 | 0.040 |
Why?
|
| Homozygote | 1 | 2020 | 124 | 0.040 |
Why?
|
| Phosphatidylinositols | 1 | 2020 | 52 | 0.040 |
Why?
|
| Glycosylation | 1 | 2020 | 138 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 90 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1380 | 0.040 |
Why?
|
| Pedigree | 1 | 2020 | 193 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2019 | 72 | 0.040 |
Why?
|
| Catheterization, Central Venous | 1 | 2020 | 87 | 0.040 |
Why?
|
| Mice | 2 | 2025 | 10844 | 0.040 |
Why?
|
| Propensity Score | 2 | 2010 | 160 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2019 | 112 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 106 | 0.040 |
Why?
|
| Animals | 3 | 2025 | 20664 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2010 | 583 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 352 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 214 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 574 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 433 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 3396 | 0.040 |
Why?
|
| Certification | 1 | 2018 | 54 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 181 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 113 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 242 | 0.030 |
Why?
|
| Competitive Bidding | 1 | 2017 | 4 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2017 | 41 | 0.030 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2017 | 19 | 0.030 |
Why?
|
| Hospital Charges | 1 | 2017 | 23 | 0.030 |
Why?
|
| Protein Aggregates | 1 | 2017 | 20 | 0.030 |
Why?
|
| Doxycycline | 1 | 2017 | 46 | 0.030 |
Why?
|
| Learning Curve | 1 | 2017 | 35 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 1592 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2017 | 292 | 0.030 |
Why?
|
| Cadaver | 1 | 2017 | 128 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2017 | 126 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2018 | 211 | 0.030 |
Why?
|
| Shock | 1 | 2016 | 33 | 0.030 |
Why?
|
| North America | 1 | 2016 | 111 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2009 | 1122 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 275 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 289 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 148 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 436 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2015 | 71 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2017 | 218 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 326 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 1644 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 671 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2015 | 61 | 0.030 |
Why?
|
| Health Care Sector | 1 | 2015 | 20 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 37 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 313 | 0.030 |
Why?
|
| Angiography | 1 | 2015 | 153 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2015 | 59 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2015 | 93 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 105 | 0.030 |
Why?
|
| Emergencies | 1 | 2014 | 121 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 317 | 0.030 |
Why?
|
| Program Development | 1 | 2015 | 207 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 2569 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 39 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 2013 | 31 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 222 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 1469 | 0.020 |
Why?
|
| Administration, Intravesical | 1 | 2012 | 13 | 0.020 |
Why?
|
| Curriculum | 1 | 2017 | 598 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 596 | 0.020 |
Why?
|
| Skilled Nursing Facilities | 1 | 2010 | 83 | 0.020 |
Why?
|
| Home Care Services | 1 | 2010 | 98 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 2009 | 23 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2009 | 56 | 0.020 |
Why?
|
| Specialization | 1 | 2009 | 81 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2679 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2009 | 66 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2009 | 100 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 170 | 0.020 |
Why?
|
| Health Services Research | 1 | 2009 | 271 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 240 | 0.020 |
Why?
|
| Acute Disease | 1 | 2009 | 672 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 609 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 777 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2009 | 322 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 564 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 1003 | 0.010 |
Why?
|